Analyst Price Target is $78.50
▲ +5.27% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Vaxcyte in the last 3 months. The average price target is $78.50, with a high forecast of $95.00 and a low forecast of $69.00. The average price target represents a 5.27% upside from the last price of $74.57.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Vaxcyte. This Buy consensus rating has held steady for over two years.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More
